Veracyte Inc.
Rating
Updated: Aug 20, 2026Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Geno...
Latest News
3 days ago · defenseworld.net
Squarepoint Ops LLC Sells 49,301 Shares of Veracyte, Inc. $VCYTSquarepoint Ops LLC decreased its holdings in Veracyte, Inc. (NASDAQ: VCYT) by 76.8% in the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 14,853 shares of the biotechnology company's stock after selling 49,301 shares during the quarter. Squarepoint Ops LLC's holdings in
5 days ago · defenseworld.net
Corient Private Wealth LP Has $9.52 Million Holdings in Veracyte, Inc. $VCYTCorient Private Wealth LP lifted its stake in shares of Veracyte, Inc. (NASDAQ: VCYT) by 26.9% in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 162,021 shares of the biotechnology company's stock after acquiring an additional 34,299 shares during the
7 days ago · seekingalpha.com
Veracyte, Inc. (VCYT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptVeracyte, Inc. (VCYT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
8 days ago · globenewswire.com
Veracyte Acquires Convergent Genomics, Expanding its Urology Diagnostics Portfolio with a Urinary Tumor DNA Testing PlatformAcquisition positions Veracyte to deliver powerful genomic insights from urine, tissue, and blood to help guide bladder cancer care across the patient journey Acquisition positions Veracyte to deliver powerful genomic insights from urine, tissue, and blood to help guide bladder cancer care across the patient journey
13 days ago · gurufocus.com
Veracyte Inc (VCYT) Shares Surge 3.3% -- What GF Score of 81 Tells InvestorsOn September 09, 2026, Veracyte Inc (VCYT) shares rose 3.3% to $43.85, reflecting a slight uptick amid a challenging price performance over the past month, whic
21 days ago · globenewswire.com
Veracyte to Participate in the Morgan Stanley 24th Annual Global Healthcare ConferenceSOUTH SAN FRANCISCO, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced it will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on Tuesday, September 15, 2026, at 7:00 a.m. Eastern Time.
27 days ago · zacks.com
Is it Worth Adding Veracyte Stock to Your Portfolio Now?VCYT's Afirma and Decipher sales momentum supports growth, while competition, macro pressures and rising investments remain key concerns.
28 days ago · zacks.com
VCYT Drops 25.3% in the Past Month. Is the Sell-Off an Opportunity?Veracyte's 25.3% sell-off improves the entry price as strong core test demand and earnings growth face valuation, reimbursement and launch risks.
1 month ago · zacks.com
Down 30.2% in 4 Weeks, Here's Why Veracyte (VCYT) Looks Ripe for a TurnaroundVeracyte (VCYT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
1 month ago · seekingalpha.com
Veracyte: Diagnostics With Favorable EconomicsVeracyte's core tests are Decipher and Afirma. Both of these tests are producing double-digit growth with improving margins. I think that bodes well for VCYT's potential as a long-term cash flow machine. Moreover, VCYT's Prosigna and TrueMRD add more long-term upside, which management hasn't yet included in its recent 2026 testing-revenue guidance.
Analyst Summary
Add to Watchlist
Select watchlists to add or remove VCYT